Midatech knows no reason for Wednesday's share price surge
AIM-listed specialty pharmaceutical group Midatech said on Thursday that it knows no reason for the jump in its share price a day earlier.
Biodexa Pharmaceuticals
3.75p
16:55 25/04/23
-11.76%
-0.50p
FTSE AIM All-Share
728.67
15:45 15/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,259.77
15:45 15/11/24
-2.70%
-535.19
Midatech said that as announced in its full-year results, it is looking into a range of non-dilutive financing options which, if successful, would enable it to deliver on its key value-driving programmes without requiring equity finance in the short-term.
"The company remains on track to deliver all R&D programmes as outlined in the statement, and expects to commence first visit dosing in the first in-human study of the company's sustained release product Q-Octreotide (MTD201) for the treatment of acromegaly and carcinoid cancer this month."
At 0945 BST, the shares were down 19.6% to 37p.